Jing Li

Position Title

Basic Science

Office Location

Karmanos Cancer Institute
4100 John R.
Hudson-Webber Cancer Research Center, Room 523
Mail Code: HW04HO
Detroit, MI 48201

Office Phone


Education Training

(2000–2003)  Ph.D. Pharmacology, National University of Singapore, Singapore
(1994–1997)  M.S. Pharmaceutical Science, West China University of Medical Sciences, Chengdu, China
(1989–1994)  B.S. Clinical Pharmacy, West China University of Medical Sciences, Chengdu, China

Postgraduate Training
(2003–2006)  Postdoctoral Fellowship, Clinical Pharmacology and Drug Development, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

Professional Experience

Faculty Appointments
(2014–Present)  Associate Professor (tenured), Department of Oncology. Wayne State University School of Medicine, Detroit, MI
(2010–Present)  Adjunct Assistant Professor, Department of Pharmaceutical Sciences, Wayne State University School of Pharmacy, Detroit, MI
(2011–2014)  Assistant Professor, Department of Oncology. Wayne State University School of Medicine, Detroit, MI
(2006–2012)  Assistant Professor, Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI
(1997–1999)  Instructor, Department of Pharmacology, Fudan University School of Pharmacy, Shanghai, China

Hospital or Other Professional Appointments
(2006–Present) Director of Pharmacology Core, Karmanos Cancer Institute, Detroit, MI

Major Professional Societies

American Society of Clinical Pharmacology and Therapeutics
American Society of Clinical Oncology
American Association of Cancer Research
American Association of Pharmaceutical Sciences

Honors and Awards

(2014) Simcyp Academic Award (first-place) in recognition of scientific research which is leading the field of IVIVE, ADME, pharmaceutics, and modeling and simulation
(2006) Presidential Trainee Award, American Society of Clinical Pharmacology and Therapeutics (ASCPT)

Courses taught

CB 7240: Principles of Cancer Therapy
CB 7990: Research Technologies in Cancer Research
PSC 3310: Principles of Drug Disposition
PSC 7040: Advanced Drug Formulation and Delivery I

Research Interests

Clinical Pharmacology of anticancer drugs
Quantitative pharmacology: population (nonlinear mixed effects) pharmacokinetic pharmacodynamic modeling; physiologically-based pharmacokinetic modeling


1. Li J, Kim S, Shields AF, Douglas KA, McHugh CI, Lawhorn-Crews JM, Wu J, Mangner TJ, LoRusso PM. Integration dynamic positron emission tomography and conventional pharmacokinetic studies to delineate plasma and tumor pharmacokinetics of FAU, a prodrug bioactivated by thymidylate synthase. J Clin Pharmacol. 2016 Apr 20. doi: 10.1002/jcph.751. [Epub ahead of print]

2. Wu J, Zhang Y, Wiegand R, Wang J, Bepler G, Li J. Quantitative analysis of intracellular nucleoside triphosphates and other polar metabolites using ion pair reversed-phase liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B 2015; 1006: 167-78. PMID: 26551209

3. Wu J, Shaw J, Dubaisi S, Valeriote F, and Li J. In vitro metabolism and drug-drug interaction potential of UTL-5g, a novel chemo- and radio-protective agent. Drug Metab Dispos 2014; 42(12): 2058-2067 PMID: 25249693

4. Li J, Kim S, Sha X, Wiegand R, Wu J, and LoRusso P. Complex disease-, gene-, and drug-drug interactions: impact of renal function, CYP2D6 status, and OCT2 activity on the pharmacokinetics of veliparib. Clin Cancer Res 2014; 20: 3931-3944 (PMID: 24947923)

5. Wu J, LoRusso P, Matherly L, Li J. Implications of plasma protein binding for pharmacokinetics and pharmacodynamics of the γ-secretase inhibitor RO4929097. Clin Cancer Res. 2012; 18: 2066-2079 (PMID: 22351688)

6. Zheng Q, Sha X, Liu J, Heath E, LoRusso P, Li J. Association of human cytochrome P450 1A1 (CYP1A1) and sulfotransferease 1A1 (SULT1A1) polymorphisms with differential metabolism and cytotoxicity of aminoflavone. Mol Cancer Ther 2010; 9: 2803-2813 (PMID: 20713530)

7. Li J, Sausville EA, Klein PJ, Morgenstern D, Leamon CP, Messmann RA, LoRusso P. Clinical pharmacokinetics and exposure-toxicity relationship of a folate-vinca alkaloid conjugate EC145 in cancer patients. J Clin Pharmacol 2009; 49:1467-1476 (PMID: 19837906)

8. Li J, Jameson MB, Baguley BC, Pili R, Baker SD. Population pharmacokinetic-pharmacodynamic (PK-PD) model of the vascular-disrupting agent 5,6-dimethylxantheone-4-acetic acid (DMXAA) in cancer patients. Clin Cancer Res 2008;14: 2102-2110 (PMID: 18381951)

9. Li J, Zhao M, He P, Hidalgo M, and Baker SD. Differential metabolism of gefitinib and erlotinib by human cytochrome P-450 enzymes. Clin Cancer Res 2007;13: 3731-3737 (PMID: 17575239)

10. Li J, Karlsson MO, Brahmer J, Sparreboom A, Zhao M, Hidalgo M, and Baker SD. CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst 2006; 98:1714-1723 (PMID: 17148773)


Complete List of Publications in MyBibliography:

Link to the Pharmacology Core:

Faculty Status

Basic Science

← Return to listing